BiotechTube

ALKS 8700 + Dimethyl Fumarate

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing Remitting Multiple Sclerosis

Conditions

Relapsing Remitting Multiple Sclerosis

Trial Timeline

Mar 15, 2017 → Jun 27, 2019

NCT ID
NCT03093324

About ALKS 8700 + Dimethyl Fumarate

ALKS 8700 + Dimethyl Fumarate is a phase 3 stage product being developed by Biogen for Relapsing Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03093324. Target conditions include Relapsing Remitting Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Remitting Multiple Sclerosis were approved

Approved (20) Terminated (2) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Interferon beta-1aMerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Rebif® (clone 484-39)MerckApproved
✅RebifMerckApproved
✅Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03093324Phase 3Completed

Competing Products

20 competing products in Relapsing Remitting Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
Placebo + PirtobrutinibEli LillyPhase 2
27
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
dirucotide + placeboEli LillyPhase 2/3
38
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRNMerckPhase 3
40
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Teriflunomide + EvobrutinibMerckPhase 3
32
Cladribine + Placebo + Microgynon®MerckPhase 1
29